Search results
The majority of treatment modes in the management of VSDs and AVSDs are safe and effective and prevent the development of PVOD and cardiac dysfunction. Keywords: Ventricular septal defect, atrioventricular septal defect, surgery, percutaneous treatment, hybrid procedure.
- Ventricular Septal Defect - StatPearls - NCBI Bookshelf
Ventricular septal defects (VSDs) are the most common...
- Treatment of anemia in patients with heart disease: a ... - PubMed
Intravenous iron may help to alleviate symptoms in patients...
- Ventricular Septal Defect - StatPearls - NCBI Bookshelf
14 kwi 2024 · Ventricular septal defects (VSDs) are the most common congenital cardiac anomaly in children and are the second most common congenital abnormality in adults, surpassed only by a bicuspid aortic valve.
14 lis 2006 · The adult who has had VSD repair needs surveillance for aortic valve dysfunction. Those adults with residual defects need continued monitoring and consideration for reoperation if there is left ventricular volume overload or progressive aortic valve dysfunction.
15 lip 2024 · How is the diagnosis of iron deficiency (ID) or iron deficiency anemia (IDA) established across different age groups, including children, adolescents, adults, and during pregnancy? Which tests are recommended for diagnosing patients with ID/IDA?
6 gru 2019 · Our approach to ID and iron deficiency anemia (IDA) involves three steps (I 3): (1) identification of ID/IDA, (2) investigation of and management of the underlying etiology of ID, and (3) iron repletion. Iron repletion options include oral and intravenous (IV) iron formulations.
1 lut 2018 · Management and treatment of anemia in older patients often require a multidisciplinary approach and detailed investigations of organ function. In this article, we review current concepts around anemias at older age, with special emphasis on etiologies, clinical implications, and innovative concepts in the management of these patients. Subjects:
3 gru 2013 · Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study. Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.
